Denver, CO, United States of America

Phillip Reigan



 

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Castle Rock, CO (US) (2021)
  • Denver, CO (US) (2016 - 2024)

Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Phillip Reigan

Introduction

Phillip Reigan is a notable inventor based in Denver, Colorado, recognized for his significant contributions to the field of cancer research. With a total of seven patents to his name, Reigan has focused on developing innovative anti-cancer compounds that target Ral GTPases, which play a crucial role in cancer growth and metastasis.

Latest Patents

Reigan's latest patents include groundbreaking methods for inhibiting the growth or metastasis of cancer in mammals by targeting Ral GTPases. His inventions provide small molecule inhibitors of Ral GTPases that are useful in these methods, along with pharmaceutical compositions containing therapeutically effective compounds. These advancements offer promising avenues for cancer treatment and highlight Reigan's commitment to improving patient outcomes.

Career Highlights

Throughout his career, Phillip Reigan has worked with prestigious institutions such as the University of Colorado and Indiana University. His research has not only contributed to the scientific community but has also paved the way for potential therapeutic applications in oncology.

Collaborations

Reigan has collaborated with esteemed colleagues, including Dan Theodorescu and Michael Fitzpatrick Wempe, further enhancing the impact of his research through shared expertise and innovative ideas.

Conclusion

Phillip Reigan's work in developing anti-cancer compounds targeting Ral GTPases exemplifies the vital role of inventors in advancing medical science. His contributions continue to inspire future research and innovation in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…